News | Novartis novartis.com

Turning personal experience into purpose-driven careers

novartis.com·9w

Supercharging R&D: How AI helps us to bring medicines to patients faster

novartis.com·9w

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

novartis.com·10w

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut

novartis.com·10w

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

novartis.com·11w

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

novartis.com·11w

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

novartis.com·11w

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

novartis.com·11w

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

novartis.com·11w

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

novartis.com·12w

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

novartis.com·13w

Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List

novartis.com·13w

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

novartis.com·14w

Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeli...

novartis.com·14w

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

novartis.com·14w

How Novartis is helping to eliminate leprosy

novartis.com·14w

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

novartis.com·17w

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

novartis.com·18w

Novartis and US government reach agreement on lowering drug prices in the US

novartis.com·21w

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

novartis.com·22w

Log in to enable infinite scrolling